Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for ?HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012.?
"The immunologic data presented at ICAAC have predictive implications for the success of this exciting new therapeutic approach to HIV and the realization of a 'functional cure' for the disease," commented Rafick-Pierre S?kaly, ?Ph.D., Co-Director & Chief Scientific Officer, the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), whose laboratory carried out the analysis.? "SB-728-T treatment results in an unprecedented and durable increase in CD4+ cells.? Importantly, our analysis shows that this is primarily due to the expansion of CD4+ T-cell types that are vital for the successful reconstitution of the immune system in HIV-infected individuals - the central and transitional memory cells."
"These data are very important because CD4 T-cells, especially memory T-cells, are precisely the cell type that we would want
See full press release
Posted in: News, Guidance, Global
Advertisement?
beezow doo doo zopittybop bop bop cordova demaryius thomas transtar 316 william daley truffles
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.